相关实验视频

Updated: Jun 8, 2025

The In ovo CAM-assay as a Xenograft Model for Sarcoma

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

对免疫调节因子的探索性分析确定L1CAM是膜软部肉瘤的预后标志物

José L Mondaza-Hernandez^1,2, Nadia Hindi^1,2,3, Antonio Fernandez-Serra⁴

¹Health Research Institute Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain.

Therapeutic advances in medical oncology

|November 6, 2024

概括

高L1CAM表达与膜软部肉瘤 (ASPS) 的生存率较差相关. 这项研究确定L1CAM作为ASPS患者的潜在预后标志物和治疗标,与PD-L1和CD8等免疫标志物一起.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

膜软部肉瘤 (ASPS) 是一种罕见的转移性瘤,对化疗反应不佳.
在ASPS中缺乏免疫检查点抑制剂 (ICI) 的预后因素和预测生物标志物.
了解免疫反应标志物对于ASPS治疗策略至关重要.

研究的目的:

在ASPS中识别预后生物标志物.
研究免疫标记物,特别是L1CAM在预测患者结果中的作用.

主要方法:

来自GEIS数据库的19名ASPS患者的回顾性分析.
针对PD-L1,CD8和其他免疫标记物的免疫组织化学.
使用HTG免疫瘤学小组进行基因表达分析.
卡普兰-梅尔对生存相关性的分析.

主要成果:

在63%的瘤中观察到PD-L1阳性;CD8+透是常见的.
高CD8密度显示了改善整体存活率的趋势.
L1CAM表达与OS负相关,并与CD8透率低相关.

结论:

在ASPS中,L1CAM是一种潜在的预后标志物和治疗标,与较差的OS相关.
PD-L1表达和CD8+透表明免疫调节疗法的潜力.
需要进行更大规模的研究来验证这些发现,并探索针对L1CAM的策略.

关键词:

一个L1CAM.气泡膜软部分肉瘤生物标志物生物标志物免疫调节剂<免疫疗法>预后生物标志物预后生物标志物

更多相关视频

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...